Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Incyte Licenses Two Treatments To Novartis

By: MarketMinute.com Stock News
Incyte Corp. (Nasdaq: INCY) will license two blood disorder and cancer treatments to Novartis for $150 million upfront and an additional $60 million milestone payment. The stock price rose 76 cents to $8.48.

Related Stocks:
Incyte Corp
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.